Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
Product Unit Size | Cost | Quantity | Stock |
---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
Cas No. | 1258595-14-0 |
---|---|
Purity | ≥99% |
Formula | C29H32F2N3O7P |
Formula Wt. | 603.56 |
IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
Synonym | LHC165 |
Appearance | Pale yellow powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet |
---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
PI3K inhibitor.
SARS-CoV-2 inhibitor
Mycotoxin, metabolite of aflatoxin B1 produced ...
Tricyclic benzonaphthyridinone; mTORC1/2 inhibi...
Selective and reversible JAK inhibitor.
Peptide, used to deliver conjugated drugs to ce...
Lipopeptide; 1,3-β-Glucan synthase inhibitor.<...
Valsartan impurity
Mixture of Ginkgolides A, B and C, found in Gin...
Recombinant BNP, cardiomodulatory peptide; NPR-...
Benzazepine derivative; D1 partial agonist, pot...
principal metabolic product of COX-2
Surfactant found in coconut oil.
JAK2 inhibitor, potential EGFR inhibitor.
Synthesis impurity
Nucleoside (deoxyguanosine) analog, ganciclovir...